Scpharmaceuticals (NASDAQ:SCPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
A number of other research firms also recently weighed in on SCPH. Leerink Swann started coverage on shares of Scpharmaceuticals in a research report on Tuesday, December 12th. They set an “outperform” rating and a $20.00 target price for the company. Jefferies Group started coverage on shares of Scpharmaceuticals in a research note on Tuesday, December 12th. They set a “buy” rating and a $23.00 price target on the stock. Finally, BMO Capital Markets started coverage on shares of Scpharmaceuticals in a research note on Tuesday, December 12th. They set an “outperform” rating and a $24.00 price target on the stock.
In other Scpharmaceuticals news, major shareholder 5Am Partners Iv, Llc purchased 654,762 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $14.00 per share, for a total transaction of $9,166,668.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
Several hedge funds have recently made changes to their positions in SCPH. AWM Investment Company Inc. purchased a new stake in shares of Scpharmaceuticals during the 4th quarter valued at approximately $1,996,000. Nicholas Investment Partners LP purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $1,500,000. Bank of New York Mellon Corp purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $414,000. Finally, Monashee Investment Management LLC purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $230,000. Institutional investors own 0.07% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/14/scpharmaceuticals-scph-cut-to-sell-at-zacks-investment-research.html.
Scpharmaceuticals Company Profile
scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.